<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119790</url>
  </required_header>
  <id_info>
    <org_study_id>283HV102</org_study_id>
    <nct_id>NCT05119790</nct_id>
  </id_info>
  <brief_title>A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects</brief_title>
  <official_title>An Open Label, Phase 1 Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of a Single Oral Dose of [14C]-BIIB122 ([14C] DNL151) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Denali Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, non-randomized, open-label Phase 1 study to determine the&#xD;
      absorption, metabolism, and excretion (AME) of BIIB122 (DNL151) following administration of a&#xD;
      single oral dose of [14C] BIIB122 ([14C] DNL151) following a fast. The mass balance,&#xD;
      excretion, and PK of BIIB122 (DNL151) will be used to evaluate AME.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass balance (total recovery) following oral administration of a single dose of [14C] BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of radioactivity recovered in urine following oral administration of a single dose of [14C] BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of radioactivity recovered in feces following oral administration of a single dose of [14C] BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: The first time to maximum observed concentration (Tmax) for total radioactivity and BIIB122 (DNL151) in blood following oral administration of a single dose of [14C]-BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Maximum observed plasma concentration (Cmax) occurring at Tmax for total radioactivity and BIIB122 (DNL151) in blood following oral administration of a single dose of [14C]-BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Area under the concentration-time curve (AUC) of total radioactivity and BIIB122 (DNL151) in blood following oral administration of a single dose of [14C]-BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Time at which half the drug has been eliminated (T1/2) of total radioactivity and BIIB122 (DNL151) in blood following oral administration of a single dose of [14C]-BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Apparent systemic clearance (CL/F) of total radioactivity and BIIB122 (DNL151) in blood following oral administration of a single dose of [14C] BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Apparent volume of distribution (Vz/F) of total reactivity and BIIB122 (DNL151) in blood following oral administration of a single dose of [14C] BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Profiles of [14C] BIIB122 ([14C]-DNL151) and its [14C] metabolites in plasma, urine, and feces following oral administration of a single dose of [14C] BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>43 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: The ratio of total radioactivity in whole blood to that in plasma following oral administration of a single dose of [14C] BIIB122 ([14C]-DNL151)</measure>
    <time_frame>43 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemical identities of the [14C] metabolites of [14C] BIIB122 ([14C]-DNL151) measured in plasma, urine, and feces</measure>
    <time_frame>43 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] BIIB122 ([14C] DNL151)</intervention_name>
    <description>Oral dose</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        key Inclusion Criteria:&#xD;
&#xD;
          -  For men who choose to have sex with women, either: vasectomy, use of condoms, or sex&#xD;
             with a woman who is of non-childbearing potential&#xD;
&#xD;
          -  Body mass index ≥18.0 kg/m2 and ≤32.0 kg/m2&#xD;
&#xD;
          -  Body weight ≥5.0 kg and ≤100.0 kg&#xD;
&#xD;
          -  Considered to be in good health&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of any condition or prior surgery that, in the opinion of the&#xD;
             investigator, poses a significant risk to subject safety and/or achievement of study&#xD;
             objectives&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Denali Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaron CPC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-706-8833</phone>
      <email>Baltimore.recruiter@pharmaron-us.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

